Mason Hawkins’s Regeneron Pharmaceuticals REGN Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$95M Buy
152,322
+21,660
+17% +$14.7M 4.95% 6
2026
Q1
$101M Sell
130,662
-35,130
-21% -$26.9M 4.97% 6
2025
Q4
$128M Buy
165,792
+21,185
+15% +$14.4M 5.7% 4
2025
Q3
$81.3M Sell
144,607
-15,974
-10% -$9.03M 4.15% 9
2025
Q2
$84.3M Buy
160,581
+45,701
+40% +$25.5M 4.25% 7
2025
Q1
$72.9M Buy
+114,880
New +$79M 3.88% 11

Other funds holding REGN

Mason Hawkins's REGN Position: Q2 2026 in Review

Mason Hawkins increased its Regeneron Pharmaceuticals (REGN) stake by 17% in Q2 2026, buying an estimated $14.7M and bringing the position to 152,322 shares worth $95M. The position accounts for 4.95% of the portfolio, ranked #6.

Mason Hawkins first reported a position in REGN in Q1 2025 and has held it in 6 quarters since. The position peaked at $128M in Q4 2025. 1,328 funds tracked by Wall St. Rank hold REGN as of Q2 2026.

  • Mason Hawkins held 152,322 shares of Regeneron Pharmaceuticals worth $95M as of Q2 2026.
  • Mason Hawkins bought 21,660 Regeneron Pharmaceuticals shares in Q2 2026, an estimated $14.7M.
  • Regeneron Pharmaceuticals made up 4.95% of Mason Hawkins's portfolio in Q2 2026, its #6 holding.
  • Mason Hawkins first reported a position in Regeneron Pharmaceuticals in Q1 2025 and has held it in 6 quarters since.
  • Mason Hawkins's Regeneron Pharmaceuticals position peaked at $128M in Q4 2025.
  • 1,328 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q2 2026.

Based on Southeastern Asset Management's 13F filing for Q2 2026, filed 14 Aug 2026.